Allspring Global Investments
TVTX icon

Allspring Global Investments’s Travere Therapeutics TVTX Stock Holding History

Allspring Global Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,014
Closed -$9.06K – 2737
2023
Q3 		$9.06K Sell
1,014
-1,513
-60% -$21.3K ﹤0.01% 2617
2023
Q2 		$38.8K Buy
2,527
+2,139
+551% +$38.9K ﹤0.01% 2345
2023
Q1 		$8.73K Sell
388
-5,141
-93% -$109K ﹤0.01% 2609
2022
Q4 		$116K Sell
5,529
-121
-2% -$2.56K ﹤0.01% 2019
2022
Q3 		$139K Hold
5,650
– – ﹤0.01% 1950
2022
Q2 		$136K Sell
5,650
-33,792
-86% -$850K ﹤0.01% 1951
2022
Q1 		$1.02M Buy
39,442
+1,686
+4% +$44.8K ﹤0.01% 1860
2021
Q4 		$1.17M Buy
+37,756
New +$1.06M ﹤0.01% 1841

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Allspring Global Investments's TVTX Position: Q4 2023 in Review

Allspring Global Investments sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 1,014 shares — an estimated $9.06K sold.

Allspring Global Investments first reported a position in TVTX in Q4 2021 and held it in 8 quarters. The position peaked at $1.17M in Q4 2021. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

  • Allspring Global Investments reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 1,014 Travere Therapeutics shares in Q4 2023, an estimated $9.06K.
  • Allspring Global Investments first reported a position in Travere Therapeutics in Q4 2021 and held it in 8 quarters.
  • Allspring Global Investments's Travere Therapeutics position peaked at $1.17M in Q4 2021.
  • 165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.